Skip to main content
. 2020 Jun 29;20:183. doi: 10.1186/s12866-020-01862-z

Table 2.

Resistance mechanisms of 76 mupirocin, fusidic acid and/or retapamulin-resistant clinical MRSA isolates

Mupirocin Fusidic acid Retapamulin
Strain Phenotype mupA mupB IleS mutation Phenotype Mutation fusB fusC fusD Phenotype Mutation cfr vagA/Av/ALC/B/C/E lsaA-C lsaE salA
Smr Mrm Lmr Fus A Fus E rplC 23S rRNA V
PT300 MuL N213D V588F S S
546 MuL N213D S S
532 MuL N213D S S
472 MuL N213D S S
526 MuL N213D S S
606 MuL N213D S S
673 MuL N213D S S
777 MuL N213D S S
635 MuL N213D S S
575 MuL N213D S S
WU9 MuL N213D V588F S S
308 MuL N213D S S
110 S FAH L461K + S
829 S FAH H457Q + S
PT301 S FAH L461K + S
PT308 S FAH L461K + S
LY26 S FAH E8K, V90I, L461K S
LY32 S FAH H457Y S
696 S FAL + S
755 S FAL + S
783 S FAL + S
361 S FAL + S
611SG S FAL + S
765 S FAL + + S
LS964 S S R +
58 S S R
486 MuH + S R
PT343 MuH + S S
355 MuH + S S
370 MuH + S S
519 MuH + S S
409 MuH + S S
671 MuH + S S
443 MuH + S S
530 MuH + S S
120 MuH + S S
322 MuH + S S
328 MuH + S S
448 MuH + S S
474 MuH + S S
565 MuH + S S
600 MuH + S S
623 MuH + S S
642 MuH + S S
694 MuH + S S
697 MuH + S S
70 MuH + S S
701 MuH + S S
717 MuH + S S
PT317 MuH + S S
318 MuH + S S
106 MuH + S S
331 MuH + S S
364 MuH + S S
553 MuH + S S
504 MuH + S S
394 MuH + S S
805 MuH + S S
453 MuH + S S
727 MuH + S S
764 MuH + S S
433 MuH + S S
541 MuH + S S
631 MuH + S S
320 MuH + S S
348 MuH + S S
349 MuH + S S
399 MuH + S S
422 MuH + S S
419 MuH + S S
390 MuH + S S
125 MuH + S S
323 MuH + S S
386 MuH + S S
513 MuH + S S
314 MuH + S S

MRSA, methicillin-resistant S. aureus; +, positive; —, negative or no mutation; IleS, isoleucyl-tRNA synthetase; MuH, high-level mupirocin resistance; MuL, low-level mupirocin resistance; FAH, high-level fusidic acid resistance; FAL, low-level fusidic acid resistance; vagA/Av/ALC/B/C/E, including vagA, vagAv, vagALC, vagB, vagC and vagE; lsaA-C, including lsaA, lsaB and lsaC R, resistance; S, susceptibility